Development
Lantern Pharma Inc.
LTRN
$3.32
-$0.11-3.21%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.96% | 16.08% | 23.26% | 16.73% | 21.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.25% | 18.10% | 5.41% | 52.37% | -48.29% |
| Operating Income | -64.25% | -18.10% | -5.41% | -52.37% | 48.29% |
| Income Before Tax | -39.60% | -5.65% | 6.16% | 4.50% | 44.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.60% | -5.65% | 6.16% | 4.50% | 44.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.60% | -5.65% | 6.16% | 4.50% | 44.14% |
| EBIT | -64.25% | -18.10% | -5.41% | -52.37% | 48.29% |
| EBITDA | -64.30% | -18.09% | -5.38% | -52.37% | 48.34% |
| EPS Basic | -39.40% | -5.40% | 6.02% | 1.80% | 42.36% |
| Normalized Basic EPS | -39.36% | -5.40% | 5.99% | -31.13% | 42.34% |
| EPS Diluted | -38.67% | -5.40% | 6.02% | 1.80% | 42.05% |
| Normalized Diluted EPS | -39.36% | -5.40% | 5.99% | -31.13% | 42.34% |
| Average Basic Shares Outstanding | 0.17% | 0.24% | -0.17% | -2.76% | -3.11% |
| Average Diluted Shares Outstanding | 0.17% | 0.24% | -0.17% | -2.76% | -3.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |